<DOC>
	<DOCNO>NCT00976248</DOCNO>
	<brief_summary>The purpose research study determine safety RAD001 ( Everolimus ) high dose drug give people safely . RAD001 ( Everolimus ) drug work prevent cell body grow divide . Information basic Phase I clinical research study suggest RAD001 also may help prevent tumor growth people relapse refractory lymphoma .</brief_summary>
	<brief_title>Everolimus ( RAD001 ) Primary Therapy Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>- Participants take RAD001 orally day morning . Each treatment cycle last four week . Participants receive 72 cycle treatment . - During cycle , participant ask visit clinic schedule test exams . They visit clinic first day first three cycle , every 3 cycle . During visit , participant physical exam blood tests.. Participants may also CT scan chest , abdomen pelvis well bone marrow aspirate biopsy .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>18 year age old Adequate liver renal function outline protocol Fasting serum cholesterol 300mg/dl less OR 7.75mmol/L less AND fast triglyceride 2.5 x institutional ULN le . Clinicopathological diagnosis Waldenstrom 's macroglobulinemia define consensus panel Second International Workshop Waldenstrom 's macroglobulinemia No previous therapy WM Measurable disease , define presence immunoglobulin M ( IgM ) paraprotein minimum IgM level 2 time upper limit institution 's normal value great require ECOG Performance status 02 Patients must life expectancy least 3 month Baseline platelet absolute neutrophil outline protocol INR PTT 1.5 x normalize ratio less A male subject agree use acceptable method contraception duration study 8 week last dose study drug Female subject either postmenopausal surgically sterilize willing use acceptable method birth control duration study 8 week last dose study drug Patients experience symptomatic hyperviscosity require plasmapheresis . This include patient , judgement investigator require urgent response eligible . These patient hyperviscosity include serum IgM level 5000 mg/dL great . Symptoms may include nosebleed , visual complication , fatigue , headache , confusion , etc . Patients , major surgery significant traumatic injury within 4 week start study drug , patient recover side effect major surgery patient may require major surgery course study . Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent . Topical inhale corticosteroid allow . Patients receive immunization attenuate live vaccine within one week study entry study period . Patients severe and/or uncontrolled medical condition condition would affect participation study . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 . Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . Patients know hypersensitivity RAD001 rapamycins excipients Patients malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell skin Patients known history HIV seropositivity History noncompliance medical regimen Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>everolimus</keyword>
	<keyword>RAD001</keyword>
	<keyword>WM</keyword>
</DOC>